Teva announces publication of new clinician scale in journal of clinical psychiatry to assess the impact of tardive dyskinesia on patients' lives

Tel aviv, israel & parsippany, n.j.--(business wire)--teva pharmaceuticals, a u.s. affiliate of teva pharmaceutical industries ltd. (nyse and tase: teva), today announced the print publication of the impact-td scale, an easy-to-use, standardized and clinician-rated assessment. the scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (td) on different aspects of a patient's daily functioning.
TEVA Ratings Summary
TEVA Quant Ranking